A Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 in Japanese Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs LY 3209590 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 Aug 2019 Status changed from active, no longer recruiting to completed.
- 15 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2019 Planned End Date changed from 28 Apr 2019 to 30 Nov 2019.